Avelumab and Merkel Cell Carcinoma: Examining Biological Plausibility
From General Health Science to Occupational Risk
The legacy heritage of general health and science information provides a broad foundation for understanding how environmental and pharmaceutical exposures can influence biological systems. Within this context, public health frameworks have long emphasized the importance of identifying risk factors that may contribute to disease development, including those arising from medical interventions. This general perspective now narrows to a specific occupational exposure concern: the potential link between Avelumab, a therapeutic agent, and the risk of Merkel Cell Carcinoma. In occupational settings, particularly within pharmaceutical manufacturing, healthcare administration, or clinical research, workers may encounter Avelumab through direct handling, accidental exposure, or environmental contamination. The transition from general health awareness to this focused occupational risk requires examining whether such exposure could plausibly contribute to carcinogenesis. While the legacy theme underscores the value of broad scientific literacy, the pivot here centers on the practical implications for worker safety. The biological plausibility of Avelumab-related Merkel Cell Carcinoma causation in occupational contexts hinges on understanding the drug’s mechanism of action and its potential to disrupt normal cellular regulation. This shift from general health information to a specific exposure scenario underscores the need for targeted risk assessment and preventive measures in workplaces where Avelumab is present.
Mechanism of Action and Therapeutic Role
Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). While avelumab is indicated for MCC, the question of whether avelumab can cause or contribute to the development of MCC requires examination of biological plausibility, mechanistic pathways, and risk considerations.
Etiology of Merkel Cell Carcinoma
MCC has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus (MCPyV), while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, checkpoint inhibitors are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can include a range of inflammatory conditions, but there is no established mechanistic pathway by which avelumab directly induces the formation of new MCC tumors. Instead, the biological plausibility of avelumab causing MCC would require evidence that the drug promotes oncogenesis or reactivates latent viral infections in a manner that leads to MCC development. Currently, the evidence does not support such a direct causal link.
Evidence Against Causation
The literature describes avelumab as a treatment for MCC, not as a causative agent. For example, studies have investigated avelumab-refractory MCC, where patients who did not respond to avelumab were subsequently treated with other immunotherapies (https://pubmed.ncbi.nlm.nih.gov/33439294/). This indicates that avelumab is used in patients who already have MCC, and its failure to control the disease does not imply causation. Regarding mechanistic pathways, avelumab's primary action is immune checkpoint inhibition, which can lead to immune-related adverse events such as sarcoidosis-related hypercalcemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, there is no evidence that avelumab triggers MCPyV reactivation or UV-induced mutations that are the known causes of MCC. In fact, the standard treatment for metastatic MCC includes anti-PD-1/PD-L1 inhibitors like avelumab, which show better overall response rates and longer duration of responses compared to chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385/). The fact that avelumab is an effective treatment for MCC argues against it being a cause of the disease. Additionally, response rates to PD-1/PD-L1 inhibition in metastatic MCC can be up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/), further supporting the therapeutic role of these agents.
Risk Considerations and Conclusion
Risk anchors include the adequacy of warnings regarding avelumab and MCC. The prescribing information for avelumab includes warnings about immune-related adverse events, but there is no specific warning that avelumab causes MCC. Given that avelumab is approved for the treatment of MCC, such a warning would be contradictory. For affected patients, causation-related considerations are important. If a patient develops MCC after exposure to avelumab, the timeline between exposure and documented harm must be evaluated. However, since avelumab is used to treat existing MCC, any new diagnosis of MCC in a patient receiving avelumab would likely be due to progression of pre-existing disease or de novo development unrelated to the drug. The literature does not report cases of avelumab-induced MCC; rather, it reports cases of avelumab-refractory MCC, where the drug fails to control the cancer (https://pubmed.ncbi.nlm.nih.gov/33439294/). The timeline between avelumab exposure and MCC diagnosis would need to consider the natural history of MCC, which can be aggressive and rapidly progressive. Without evidence of a causal mechanism, it is not plausible that avelumab causes MCC. In summary, the biological plausibility of avelumab causing Merkel cell carcinoma is not supported by current evidence. Avelumab is an immune checkpoint inhibitor used to treat MCC, and its mechanism of action does not involve oncogenesis. The known etiologies of MCC are MCPyV infection and UV-induced mutations, neither of which are linked to avelumab. Risk considerations, including warnings and causation, do not support a causal relationship. Patients and clinicians should be aware that avelumab is a treatment for MCC, not a cause.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Can avelumab cause Merkel cell carcinoma?
Current evidence does not support that avelumab causes Merkel cell carcinoma. Avelumab is an immune checkpoint inhibitor used to treat MCC, and its mechanism of action does not involve oncogenesis. The known causes of MCC are MCPyV infection and UV-induced mutations, neither of which are linked to avelumab (https://pubmed.ncbi.nlm.nih.gov/34445385/).
What is the biological plausibility of avelumab causing MCC?
There is no established mechanistic pathway by which avelumab directly induces new MCC tumors. Avelumab works by blocking PD-L1 to enhance immune response against existing cancer cells, and while it can cause immune-related adverse events, there is no evidence it triggers viral reactivation or mutations that lead to MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.